Physician profile
Beatriz Alvarez
NPI 1558955922
$5,597.09
in general payments reported to CMS, 2019-2025
29 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $686 · 2023: $1,103 · 2024: $1,052 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,125 · Education: $278 · Consulting Fee: $17.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,124.94 |
| Education | $277.82 |
| Consulting Fee | $17.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $762.69 | 2021-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $730.73 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $545.74 | 2021-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $490.17 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Genzyme Corporation | $433.14 | 2021-2025 | |
| Amgen INC. | $388.64 | 2021-2025 | Tezspire |
| Csl Behring | $370.15 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $342.92 | 2023-2025 | |
| Genentech USA, INC. | $229.41 | 2023-2025 | Xolair |
| Optinose US, INC. | $211.11 | 2023-2025 | |
| Phadia US INC. | $137.39 | 2021-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $132.23 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $123.35 | 2025 | Neffy |
| Pharming Healthcare, INC. | $114.93 | 2024-2025 | Ruconest |
| Covis Pharma Gmbh | $82.15 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $77.24 | 2022-2023 | Auvi-Q |
| Hikma Pharmaceuticals USA | $76.85 | 2023-2025 | Ryaltris |
| Leo Pharma INC. | $68.45 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $52.39 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $42.47 | 2025 | Dawnzera |
| Gilead Sciences, INC. | $40.07 | 2024 | |
| Aimmune Therapeutics, INC. | $23.48 | 2022 | |
| Organon LLC | $21.82 | 2025 | |
| Grifols USA, LLC | $18.52 | 2025 | Xembify |
| Adma Biomanufacturing LLC | $17.92 | 2024 | |
| Abbvie INC. | $17.38 | 2022 | |
| Blueprint Medicines Corporation | $16.38 | 2023 | Ayvakit |
| Pfizer INC. | $15.75 | 2022 | |
| Incyte Corporation | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.